Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui(Southern Medical University), Martin P. Edwards(Pfizer (United States)), Neil B. Grodsky(Pfizer (United States)), Helen Y. Zou(Centre for Cancer Biology), Barbara Mroczkowski(Pfizer (United States)), Mitchell D. Nambu(Pfizer (United States)), Michele McTigue(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Shinji Yamazaki, Pei‐Pei Kung(Pfizer (United States)), Hong Shen(University of Michigan), Lee Funk(Pfizer (United States)), Iriny Botrous(Pfizer (United States)), Sergei Timofeevski(Pfizer (United States)), Ellen Padrique(Pfizer (United States)), Jerry Meng(Pfizer (United States)), Steve Bender(Pfizer (United States)), James G. Christensen, Michelle Tran‐Dubé(Pfizer (United States)), Mason Pairish(Pfizer (United States)), Gordon Alton(Pfizer (United States)), Kevin Ryan(Pfizer (United States)), Qiuhua Li(Pfizer (United States)), Lei Jia(Pfizer (United States))
Cited by 924
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
|Cancer Cell|2010|1.1k
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
|Cancer Research|2007|750